These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 12034670

  • 1. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties.
    Peter K, Schwarz M, Bode C.
    Circulation; 2002 May 28; 105(21):E180-1. PubMed ID: 12034670
    [No Abstract] [Full Text] [Related]

  • 2. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 3. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 14; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 4. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.
    Blood; 1998 Nov 01; 92(9):3240-9. PubMed ID: 9787160
    [Abstract] [Full Text] [Related]

  • 5. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 01; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 6. Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor.
    Weisman HF, Schaible TF, Jordan RE, Cabot CF, Anderson KM.
    Biochem Soc Trans; 1995 Nov 01; 23(4):1051-7. PubMed ID: 8654680
    [No Abstract] [Full Text] [Related]

  • 7. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 8. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 15; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 9. Platelet receptors.
    Blom P, Korona M, Haikal L.
    AJNR Am J Neuroradiol; 2006 Jan 15; 27(1):8-9; author reply 9. PubMed ID: 16418346
    [No Abstract] [Full Text] [Related]

  • 10. Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes.
    Ndoko S, Poujol C, Combrié R, Nurden A, Nurden P.
    Thromb Haemost; 2002 Feb 15; 87(2):317-22. PubMed ID: 11858493
    [Abstract] [Full Text] [Related]

  • 11. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 12. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K, Sato K, Kamohara M, Kaku S, Kawasaki T, Yano S, Iizumi Y.
    Biol Pharm Bull; 2002 Aug 04; 25(8):1006-12. PubMed ID: 12186399
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S, Nishikawa M, Onoda K, Shimono T, Shimpo H, Yazaki A, Tanaka K, Shiku H, Yada I.
    J Thorac Cardiovasc Surg; 2003 Aug 04; 126(2):428-35. PubMed ID: 12928640
    [Abstract] [Full Text] [Related]

  • 16. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE.
    Thromb Haemost; 2001 Feb 04; 85(2):309-13. PubMed ID: 11246553
    [Abstract] [Full Text] [Related]

  • 17. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C.
    Am J Cardiol; 1999 Sep 01; 84(5):519-24. PubMed ID: 10482148
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA, Khurana S, Forsythe MS.
    Arterioscler Thromb Vasc Biol; 2000 Apr 01; 20(4):1162-7. PubMed ID: 10764688
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Abciximab (ReoPro) removal with a hemoconcentrator during cardiopulmonary bypass.
    Lemmer JH.
    J Thorac Cardiovasc Surg; 1999 Nov 01; 118(5):980-1. PubMed ID: 10534719
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.